NA
REGN icon

Nautilus Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Nautilus Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-333
Closed -$211K – 166
2025
Q1 		$211K Buy
333
+35
+12% +$24.1K 0.17% 149
2024
Q4 		$212K Buy
+298
New +$250K 0.17% 145

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nautilus Advisors's REGN Position: Q2 2025 in Review

Nautilus Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 333 shares — an estimated $211K sold.

Nautilus Advisors first reported a position in REGN in Q4 2024 and held it in 2 quarters. The position peaked at $212K in Q4 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Nautilus Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Nautilus Advisors sold 333 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $211K.
  • Nautilus Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Nautilus Advisors's Regeneron Pharmaceuticals position peaked at $212K in Q4 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Nautilus Advisors's 13F filing for Q2 2025, filed 26 Aug 2025.